Experience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failure
https://doi.org/10.18087/cardio.2477
Abstract
Le article discusses management of a female patient with chronic heart failure with reduced left ventricular ejection fraction after an episode of acute decompensation. Replacing an angiotensin-converting enzyme inhibitor with a representative of a new angiotensin receptor-neprilysin inhibitor class, sacubitril/valsartan, in the combination therapy allowed fast achievement and maintenance of the compensation state. RAe treatment was well tolerated and was not associated with clinically significant adverse effects.
Keywords
хроническая сердечная недостаточность со сниженной фракцией выброса левого желудочка,
острая декомпенсация хронической сердечной недостаточности,
ангиотензиновых рецепторов и неприлизина ингибитор,
сакубитрил/валсартан,
HFrEF,
acute decompensation of chronic heart failure,
angiotensin receptor-neprilysin inhibitor,
sacubitril/valsartan
About the Authors
S. A. Galochkin
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
O. I. Lukina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
I. A. Meray
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
S. V. Villevalde
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Zh. D. Kobalava
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
References
1. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007,93 (9):1137-46. DOI:10.1136/hrt. 2003.025270
2. Dunlay SM, Roger V.L. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Current Heart Failure Reports. 2014,11 (4):404-15. DOI:10.1007/s11897-014-0220-x
3. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017,18 (1):3-40. DOI:10.18087/rhfj. 2017.1.2346
4. Ponikowski P., Voors AA, Anker SD, Bueno H., Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37 (27):2129-200. DOI:10.1093/eurheartj/ehw128
5. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017,136 (6):e137-61. DOI:10.1161/CIR. 0000000000000509
6. Hubers SA, Brown N.J. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016,133 (11):1115-24. DOI:10.1161/CIRCULATIONAHA. 115.018622
7. McMurray JJV, Packer M., Desai AS, Gong J., Lefkowitz MP, Rizkala AR et al. Angiotensin - niprilysin Inhibition versus enalapril in heart failure. New EnglandJournal of Medicine. 2014,371 (11):993-1004. DOI:10.1056/NEJMoa1409077
8. Jhund PS, Fu M., Bayram E., Chen C-H, Negrusz-Kawecka M., Rosenthal A. et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) ac cording to age: insights from PARADIGM-HF. European Heart Journal. 2015,36 (38):2576-84. DOI:10.1093/eurheartj/ehv330
9. Solomon SD, Claggett B., Desai AS, Packer M., Zile M., Swedberg K. et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circulation: Heart Failure. 2016,9 (3):e002744. DOI:10.1161/CIRCHEART-FAILURE. 115.002744
10. Kristensen SL, Preiss D., Jhund PS, Squire I., Cardoso JS, Merkely B. et al. Risk Related to Pre - Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction CLINICAL PERSPECTIVE: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circulation: Heart Failure. 2016,9 (1):e002560. DOI:10.1161/ CIRCHEARTFAILURE. 115.002560
11. Böhm M., Young R., Jhund PS, Solomon SD, Gong J., Lefkowitz MP et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017,38 (15):1132-43. DOI:10.1093/eur-heartj/ehw570
12. Mogensen U. Sunday 28 August 2016. European Heart Journal. 2016,37 (suppl 1 ): 193. DOI:10.1093/eurheartj/ehw432
13. Damman K. Monday, 31 August 2015. European Heart Journal. 2015,36 (suppl 1):509-847. DOI:10.1093/eurheartj/ehv400
14. Desai AS, McMurray JJV Packer M., Swedberg K., Rouleau JL, Chen F. et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015,36(30):1990-7. DOI:10.1093/eurheartj/ehv186
Review
For citations:
Galochkin S.A., Lukina O.I., Meray I.A., Villevalde S.V., Kobalava Zh.D. Experience of hospital initiation of sacubitril/valsartan in a female patient after acute decompensated heart failure. Kardiologiia. 2018;58(5S):60-64. (In Russ.) https://doi.org/10.18087/cardio.2477
Views:
1069
Email this article 
Post a Comment 
